Mirvetuximab (M9346A) is a novel folate receptor alpha (FRalpha) monoclonal antibody targeting anti-FOLR1 (folate receptor 1). Mirvetuximab soravtansine is often conjugated with platinum compounds or other compounds to form antibody-drug conjugates for the treatment of ovarian cancer and other FRalpha-positive cancers.
Reinheit:
>95%
CAS Nummer:
[1453084-36-0]
Target-Kategorie:
Antifolate|||ADC Antibody
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten